Health ❯ Healthcare ❯ Patient Outcomes

Weight Management

Glycemic Control Treatment Efficacy Health Improvements Medication Adherence Obesity Treatment Obesity Long-term Efficacy Obesity Treatments Medication Accessibility

Meta-Analysis Finds Tirzepatide Produces Largest Average Weight Loss Among FDA‑Approved GLP‑1s

Linked to dual GLP‑1/GIP targeting, tirzepatide showed larger average weight loss in trials with uncertain post‑treatment durability.

Innovent Says Mazdutide Tops Semaglutide in China Phase 3 Diabetes Trial

Tufts Chemists Unveil Four-Receptor Obesity Drug to Challenge Bariatric Surgery